HBOT Conversations:
Join us for interviews with researchers, practitioners, industry experts, and patients to share their stories, successes, and expertise relative to hyperbaric oxygen therapy
Subscribe. Join the discussion. Share the hope.
Listen to or Watch the HBOT Conversations Podcast
Listen to the HBOT Converstations podcast by downloading it from your favorite podcasting platform or scroll down and watch an episode here on the HBOT News website:
Watch the HBOT Conversations Podcast
Subscribe Now, It’s Free !
Recent HBOT News
Clinical Trial – Heavy Bupivacaine in Peribulbar Block
Most of the ophthalmic procedures are performed under local anesthesia as the patient is
often elderly and with diseases. This may increase the risk of morbidity and mortality under
general anesthesia. Different eye blocks have been practiced with great success. Moreover, it
is associated with less hemodynamic instability, less respiratory depression, better
postoperative pain relief, and less nausea and vomiting than general anesthesia. It is also
associated with a reduction in stress response, maintained oxygen saturation and
cardiovascular stability, in addition to the production of good akinesia and anesthesia
alleviating occulo-medullary reflexes, all make local anesthesia more superior and safe
technique.
Comparison of the effects of albumin and crystalloid on mortality among patients with septic shock: systematic review with meta-analysis and trial sequential analysis.
Abstract: This study aimed to compare the effects on mortality of albumin and crystalloid, used for fluid resuscitation among adult patients with septic shock, through conducting a meta-analysis and trial sequential analysis (TSA). Meta-analysis and TSA conducted at...
Interventions for managing medication-related osteonecrosis of the jaw.
Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab and antiangiogenic agents) and...